{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:47:30Z","timestamp":1789469250960,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201233","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T12:01:55Z","timestamp":1779537715000},"page":"201233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A multimodal viro-immunotherapy strategy for glioblastoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-5839","authenticated-orcid":false,"given":"Yanhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201233_bib1","article-title":"Developing a Multimodal Therapy for Glioblastoma Using Oncolytic Virus Delivering Cd19 and Egfrviii Antigens and Bi-Specific Cars","author":"Li","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201233_bib2","first-page":"360","article-title":"Glioblastoma Microenvironment-from Biology to Therapy","volume":"38","author":"Read","year":"2024","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2026.201233_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","article-title":"Car-T Cell Therapy for the Treatment of Adult High-Grade Gliomas","volume":"8","author":"Park","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201233_bib4","article-title":"A Single Dose of Peripherally Infused Egfrviii-Directed Car T Cells Mediates Antigen Loss and Induces Adaptive Resistance in Patients with Recurrent Glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201233_bib5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from Car T-Cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201233_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective Combination Immunotherapy Using Oncolytic Viruses to Deliver Car Targets to Solid Tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201233_bib7","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","article-title":"Car-Engineered Nk Cells for the Treatment of Glioblastoma: Turning Innate Effectors into Precision Tools for Cancer Immunotherapy","volume":"10","author":"Burger","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201233_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114867","article-title":"Developing Enhanced Immunotherapy Using Nkg2a Knockout Human Pluripotent Stem Cell-Derived Nk Cells","volume":"43","author":"Qin","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201233_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.stem.2018.07.007","article-title":"Off-the-Shelf Car-Nk Cells for Cancer Immunotherapy","volume":"23","author":"Siegler","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omton.2026.201233_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human Ipsc-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-Tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:20:29Z","timestamp":1783326029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926001098"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201233","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multimodal viro-immunotherapy strategy for glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201233"}}